LONG-TERM FOLLOW-UP OF DIDANOSINE ADMINISTERED ORALLY TWICE DAILY TO PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION AND HEMATOLOGIC INTOLERANCE OF ZIDOVUDINE

被引:15
作者
ALLAN, JD [1 ]
CONNOLLY, KJ [1 ]
FITCH, H [1 ]
JACKSONPOPE, L [1 ]
MCLAREN, C [1 ]
CANETTA, R [1 ]
GROOPMAN, JE [1 ]
机构
[1] BRISTOL MYERS SQUIBB PHARMACEUT RES INST,WALLINGFORD,CT
关键词
D O I
10.1093/clinids/16.Supplement_1.S46
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This phase 1 trial was conducted to evaluate the safety and tolerance of didanosine (ddI) in subjects with AIDS or AIDS-related complex (ARC) who previously had demonstrated hematologic intolerance of zidovudine. Thirty subjects, 21 with AIDS and nine with ARC, were enrolled. Initially, didanosine was administered orally twice daily for a total daily dose of either 750 mg or 1,500 mg. Subsequently, the dosage for those receiving 1,500 mg/d was reduced to a maximum of 750 mg/d (375 mg twice daily) when data from this and other phase 1 studies showed that the dosage of 1,500 mg/d (750 mg twice daily) was associated with an unacceptable risk of developing neuropathy. The subjects were studied for 46 weeks (mean time; range, 7-122 weeks). The dose-limiting toxic effect observed was peripheral neuropathy, which occurred in eight patients. Other significant toxic effects included pancreatitis in three patients and xerostomia in eleven. In general, didanosine was well tolerated from a hematologic standpoint by the majority of patients during prolonged administration.
引用
收藏
页码:S46 / S51
页数:6
相关论文
共 30 条
[1]  
BACH MC, 1991, 7 INT C AIDS FLOR
[2]   ZIDOVUDINE SENSITIVITY OF HUMAN IMMUNODEFICIENCY VIRUSES FROM HIGH-RISK, SYMPTOM-FREE INDIVIDUALS DURING THERAPY [J].
BOUCHER, CAB ;
TERSMETTE, M ;
LANGE, JMA ;
KELLAM, P ;
DEGOEDE, REY ;
MULDER, JW ;
DARBY, G ;
GOUDSMIT, J ;
LARDER, BA .
LANCET, 1990, 336 (8715) :585-590
[3]   A PILOT-STUDY OF LOW-DOSE ZIDOVUDINE IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
COLLIER, AC ;
BOZZETTE, S ;
COOMBS, RW ;
CAUSEY, DM ;
SCHOENFELD, DA ;
SPECTOR, SA ;
PETTINELLI, CB ;
DAVIES, G ;
RICHMAN, DD ;
LEEDOM, JM ;
KIDD, P ;
COREY, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) :1015-1021
[4]   PHASE-I STUDY OF 2'-3'-DIDEOXYINOSINE ADMINISTERED ORALLY TWICE DAILY TO PATIENTS WITH AIDS OR AIDS-RELATED COMPLEX AND HEMATOLOGIC INTOLERANCE TO ZIDOVUDINE [J].
CONNOLLY, KJ ;
ALLAN, JD ;
FITCH, H ;
JACKSONPOPE, L ;
MCLAREN, C ;
CANETTA, R ;
GROOPMAN, JE .
AMERICAN JOURNAL OF MEDICINE, 1991, 91 (05) :471-478
[5]   ONCE-DAILY ADMINISTRATION OF 2',3'-DIDEOXYINOSINE (DDI) IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME OR AIDS-RELATED COMPLEX - RESULTS OF A PHASE-I TRIAL [J].
COOLEY, TP ;
KUNCHES, LM ;
SAUNDERS, CA ;
RITTER, JK ;
PERKINS, CJ ;
MCLAREN, C ;
MCCAFFREY, RP ;
LIEBMAN, HA .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (19) :1340-1345
[6]   SURVIVAL EXPERIENCE AMONG PATIENTS WITH AIDS RECEIVING ZIDOVUDINE - FOLLOW-UP OF PATIENTS IN A COMPASSIONATE PLEA PROGRAM [J].
CREAGHKIRK, T ;
DOI, P ;
ANDREWS, E ;
NUSINOFFLEHRMAN, S ;
TILSON, H ;
HOTH, D ;
BARRY, DW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (20) :3009-3015
[7]  
FISCHL MA, 1989, JAMA-J AM MED ASSOC, V262, P2405
[8]   THE SAFETY AND EFFICACY OF ZIDOVUDINE (AZT) IN THE TREATMENT OF SUBJECTS WITH MILDLY SYMPTOMATIC HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (HIV) INFECTION - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
HANSEN, N ;
COLLIER, AC ;
CAREY, JT ;
PARA, MF ;
HARDY, WD ;
DOLIN, R ;
POWDERLY, WG ;
ALLAN, JD ;
WONG, B ;
MERIGAN, TC ;
MCAULIFFE, VJ ;
HYSLOP, NE ;
RHAME, FS ;
BALFOUR, HH ;
SPECTOR, SA ;
VOLBERDING, P ;
PETTINELLI, C ;
ANDERSON, J .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (10) :727-737
[9]   THE EFFICACY OF AZIDOTHYMIDINE (AZT) IN THE TREATMENT OF PATIENTS WITH AIDS AND AIDS-RELATED COMPLEX - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISCHL, MA ;
RICHMAN, DD ;
GRIECO, MH ;
GOTTLIEB, MS ;
VOLBERDING, PA ;
LASKIN, OL ;
LEEDOM, JM ;
GROOPMAN, JE ;
MILDVAN, D ;
SCHOOLEY, RT ;
JACKSON, GG ;
DURACK, DT ;
KING, D .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (04) :185-191
[10]   A RANDOMIZED CONTROLLED TRIAL OF A REDUCED DAILY DOSE OF ZIDOVUDINE IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
FISCHL, MA ;
PARKER, CB ;
PETTINELLI, C ;
WULFSOHN, M ;
HIRSCH, MS ;
COLLIER, AC ;
ANTONISKIS, D ;
HO, M ;
RICHMAN, DD ;
FUCHS, E ;
MERIGAN, TC ;
REICHMAN, RC ;
GOLD, J ;
STEIGBIGEL, N ;
LEOUNG, GS ;
RASHEED, S ;
TSIATIS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 323 (15) :1009-1014